Which of the following statements is/are correct regarding the recent CDSCO approval of Durvalumab?
1. Durvalumab is a monoclonal antibody that acts as a checkpoint inhibitor by blocking the PD-L1 protein.
2. It was approved as India's first perioperative immunotherapy approach specifically for non-small cell lung cancer.

Question

Accepted Answer

A) 1 only — Statement 1 is correct as Durvalumab blocks PD-L1 to activate T-cells against tumors. Statement 2 is incorrect because the recent CDSCO approval is specifically for resectable gastric and gastroesophageal junction adenocarcinoma, not lung cancer.

CDSCO Approves Durvalumab Immunotherapy for Gastric Cancer

IQAir World Air Quality Report 2025 Publication